Axonics Modulation Technologies, Inc., a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention. Its proprietary r-SNM System delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of urinary and fecal dysfunction. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was founded in 2012 and is based in Irvine, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone949-396-6322
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$710,000.00
Profitability
Miscellaneous
Employees87
Next Earnings Date12/10/2019 (Estimated)
OptionableNot Optionable
Axonics Modulation Technologies (NASDAQ:AXNX) Frequently Asked Questions
What is Axonics Modulation Technologies' stock symbol?
Axonics Modulation Technologies trades on the NASDAQ under the ticker symbol "AXNX."
How were Axonics Modulation Technologies' earnings last quarter?
Axonics Modulation Technologies Inc (NASDAQ:AXNX) released its quarterly earnings data on Monday, August, 5th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.17. The company had revenue of $1.49 million for the quarter, compared to the consensus estimate of $1.04 million. Axonics Modulation Technologies had a negative net margin of 1,515.61% and a negative return on equity of 59.67%. Axonics Modulation Technologies's revenue was up 12300.0% on a year-over-year basis. View Axonics Modulation Technologies' Earnings History.
When is Axonics Modulation Technologies' next earnings date?
What price target have analysts set for AXNX?
7 equities research analysts have issued twelve-month price targets for Axonics Modulation Technologies' stock. Their forecasts range from $14.92 to $47.00. On average, they expect Axonics Modulation Technologies' share price to reach $37.1533 in the next twelve months. This suggests a possible upside of 16.3% from the stock's current price. View Analyst Price Targets for Axonics Modulation Technologies.
What is the consensus analysts' recommendation for Axonics Modulation Technologies?
Has Axonics Modulation Technologies been receiving favorable news coverage?
Media headlines about AXNX stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Axonics Modulation Technologies earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Axonics Modulation Technologies.
Are investors shorting Axonics Modulation Technologies?
Axonics Modulation Technologies saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 2,485,200 shares, an increase of 37.0% from the July 31st total of 1,813,900 shares. Based on an average trading volume of 243,900 shares, the short-interest ratio is presently 10.2 days. Approximately 26.0% of the shares of the company are sold short. View Axonics Modulation Technologies' Current Options Chain.
Who are some of Axonics Modulation Technologies' key competitors?
Some companies that are related to Axonics Modulation Technologies include NuVasive (NUVA), ICU Medical (ICUI), Nevro (NVRO), Glaukos (GKOS), Irhythm Technologies (IRTC), Cardiovascular Systems (CSII), Merit Medical Systems (MMSI), Atrion (ATRI), Cryolife (CRY), Silk Road Medical (SILK), Luminex (LMNX), Tactile Systems Technology (TCMD), AtriCure (ATRC), Orthofix Medical (OFIX) and Shockwave Medical (SWAV).
What other stocks do shareholders of Axonics Modulation Technologies own?
Who are Axonics Modulation Technologies' key executives?
Axonics Modulation Technologies' management team includes the folowing people:
- Mr. Raymond W. Cohen, CEO & Director (Age 60)
- Mr. Danny L. Dearen, Pres & CFO (Age 56)
- Dr. Karen L. Noblett M.D., M.A.S., Chief Medical Officer (Age 56)
- Mr. Rinda K. Sama, Chief Operating Officer (Age 40)
- Mr. Guangqiang Jiang Ph.D., Chief Technology Officer (Age 46)
When did Axonics Modulation Technologies IPO?
(AXNX) raised $100 million in an IPO on Wednesday, October 31st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.
Who are Axonics Modulation Technologies' major shareholders?
Axonics Modulation Technologies' stock is owned by many different of retail and institutional investors. Top institutional investors include Cormorant Asset Management LP (4.39%), BlackRock Inc. (3.32%), Vanguard Group Inc. (1.81%), Perceptive Advisors LLC (1.00%), JPMorgan Chase & Co. (0.84%) and Northern Trust Corp (0.37%). Company insiders that own Axonics Modulation Technologies stock include Bakker Juliet Tammenoms, Cormorant Asset Management, Lp, Geoff Pardo, Healthcare Holding BV Gilde, Michael V Williamson, Nancy Lynn Md Snyderman, Raymond W Cohen and Rinda Sama. View Institutional Ownership Trends for Axonics Modulation Technologies.
Which institutional investors are selling Axonics Modulation Technologies stock?
AXNX stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Cormorant Asset Management LP, Granite Investment Partners LLC and Wells Fargo & Company MN. Company insiders that have sold Axonics Modulation Technologies company stock in the last year include Geoff Pardo, Michael V Williamson and Rinda Sama. View Insider Buying and Selling for Axonics Modulation Technologies.
Which institutional investors are buying Axonics Modulation Technologies stock?
AXNX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Invesco Ltd., Nuveen Asset Management LLC, Bank of New York Mellon Corp, Citadel Advisors LLC, Parametric Portfolio Associates LLC and Balyasny Asset Management LLC. Company insiders that have bought Axonics Modulation Technologies stock in the last two years include Bakker Juliet Tammenoms, Cormorant Asset Management, Lp, Healthcare Holding BV Gilde, Nancy Lynn Md Snyderman and Raymond W Cohen. View Insider Buying and Selling for Axonics Modulation Technologies.
How do I buy shares of Axonics Modulation Technologies?
Shares of AXNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Axonics Modulation Technologies' stock price today?
One share of AXNX stock can currently be purchased for approximately $31.94.
How big of a company is Axonics Modulation Technologies?
Axonics Modulation Technologies has a market capitalization of $911.09 million and generates $710,000.00 in revenue each year. The company earns $-32,480,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Axonics Modulation Technologies employs 87 workers across the globe.View Additional Information About Axonics Modulation Technologies.
What is Axonics Modulation Technologies' official website?
How can I contact Axonics Modulation Technologies?
Axonics Modulation Technologies' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company can be reached via phone at 949-396-6322.
MarketBeat Community Rating for Axonics Modulation Technologies (NASDAQ AXNX)
MarketBeat's community ratings are surveys of what our community members think about Axonics Modulation Technologies and other stocks. Vote "Outperform" if you believe AXNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
